Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sana Biotechnology (SANA) Stock Price & Analysis

906 Followers

SANA Stock Chart & Stats

$2.37$0.03(1.28%)
At close: 4:00 PM EST
$2.5$3$3.5$4Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$2.28 - $2.49
52-Week Range
$2.22 - $5.49
Previous Close
$2.34
Volume
N/A
Average Volume (3M)
3.03M
Market Cap
$710.13M
Enterprise Value
$828.47M
Total Cash (Recent Filing)
$121.73M
Total Debt (Recent Filing)
$53.84M
Price to Earnings (P/E)
―
Beta
1.68
Next Earnings
Mar 23, 2027 (Est.)
EPS Estimate
-0.16
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Loss Trend

The narrowing loss profile indicates improving cost discipline and operating efficiency despite Sana remaining pre-revenue. If sustained, lower annual losses can extend financial runway, reduce future funding needs, and support continued investment in the clinical pipeline.

Lower Leverage

Declining debt and a lower debt-to-equity ratio give Sana a more manageable capital structure for a development-stage biotech. Reduced leverage can limit interest and refinancing pressure, preserving flexibility to prioritize research, trials, and strategic funding decisions.

Pipeline Progress

Clinical validation for UP421 and progress toward SC451 IND readiness strengthen the scientific foundation of Sana’s hypoimmune cell-therapy strategy. Advancement toward a Phase 1/2 trial could create future development milestones and improve the prospect of eventual pipeline monetization.

Bears Say

No Commercial Revenue

Sana has no commercial revenue base to fund operations, validate market demand, or offset research spending. The company therefore remains dependent on successful clinical development and future commercialization, leaving financial performance highly exposed to pipeline outcomes.

Persistent Cash Burn

Material ongoing cash burn means Sana consumes capital while advancing its programs and cannot currently self-fund operations. Unless revenue generation improves or spending falls further, continued negative free cash flow will require external financing or other sources of capital.

Shrinking Equity Base

The substantial decline in equity shows that accumulated losses have materially reduced the capital base supporting Sana’s business. Deeply negative returns on equity indicate ongoing value erosion, limiting resilience and increasing the importance of future operating or financing progress.

Sana Biotechnology News

SANA FAQ

What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $2.22 and its highest was $5.49 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $710.13M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 132 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 05, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.218.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.16.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 299,634,950 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Hedge funds hold Sana Biotechnology shares: the largest hedge-fund position in Sana Biotechnology is 70,143,991 shares, and hedge funds increased their holdings by 21.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology